Form 10-K Dianthus Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
March 12, 2025 7:39 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)
The analyst comments "We are reiterating our Buy Rating on DNTH following their 4Q24 update. DNTH remains one of our favorite ideas for 2025 based on our broader view... More
